September 2014

Catalent, Cingulate Therapeutics ink agreement for new ADHD treatments

Tuesday, September 30, 2014

Catalent Pharma Solutions, headquartered in Somerset, N.J., has reached an exclusive development and licensing agreement with Cingulate Therapeutics (CTx), a Morristown, N.J.-based, privately held biopharmaceutical company, to support development of a series of new prescription pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) using Catalent’s OSDrC OptiDose drug delivery platform.

[Read More]

Novo Nordisk establishes obesity research unit in Seattle

Tuesday, September 30, 2014

Novo Nordisk will establish a new obesity research unit in Seattle, Wash. The new unit is a result of Novo Nordisk’s increasing focus on obesity. Its main task will be to identify novel approaches and targets for obesity treatments, while increasing the scientific understanding of existing obesity targets.

[Read More]

Cybersecurity in Global Trials

Monday, September 29, 2014

The Pulse on Global Trials by Matthew Howes

Massive data breaches have dominated global headlines in recent months, and security experts predict this trend will continue.

[Read More]